Angela Gelli, Ph.D. for UC Davis Health

Angela Gelli, Ph.D.

Professor, Department of Pharmacology




Neuroinfectious Diseases



Locations and Contact

Genome and Biomedical Sciences Building

Genome & Biomedical Sciences Facility
451 Health Sciences Drive
Davis, CA 95616

Get Directions

Phone: 530-752-3200

Additional Numbers



Research/Academic Interests

Dr. Gelli's research focuses on resolving the molecular mechanisms of neuroinfectious diseases to identify targets for the development of novel therapies.



Undergraduate School

B.Sc., University of Toronto, Toronto, Ontario, Canada 1989

Other School

M.Sc., Electrophysiology, University of Toronto, Toronto, Ontario, Canada 1991

Other School

Ph.D., Cell-Molecular Biology, University of Toronto, Toronto, Ontario, Canada 1997


Post-Doctoral Research, Mount Sinai Hospital, Toronto, Ontario, Canada 1997-2000

Selected, Top Women-led Technology Companies, Sacramento CA, Fourth Wave, 2017

Elected, Councilor West for Medical Mycologists Society of the Americas, MMSA, 2015

Faculty 1000Prime, 2014

Hartwell Investigator, The Hartwell Foundation, 2012

ID Week 2012TM Program Committee Choice Award, Infectious Diseases Society of America - 50th Annual Infectious Disease Society of America (IDSA) Meeting - San Diego CA, 2012

UC Davis Research Travel Award - Invited Symposium Speaker, 7th International, Conference Cryptococcus & Cryptococcosis, Nagasaki Japan, 2008

Finalist, Burroughs Wellcome Scholar - Infectious Disease, 2016

NSERC Post-Doctoral Scholar, (Natural Science and Engineering Research Council of Canada), 1998

To view the PubMed publications list for Dr. Gelli, click here 

Aaron PA, Vu K, Gelli A. An Antivirulence Approach for Preventing Cryptococcus neoformans from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease. mBio. 2020 Jul 21;11(4):e01249-20. doi:10.1128/mBio.01249-20. PMID:32694141.

Aaron PA, Gelli A. Harnessing the Activity of the Fungal Metalloprotease, Mpr1, To Promote Crossing of Nanocarriers through the Blood-Brain Barrier. ACS Infect Dis. 2020 Jan 10;6(1):138-149. doi:10.1021/acsinfecdis.9b00348. Epub 2019 Dec 18. PMID:31820926.

Vu K, Garcia JA, Gelli A. Cryptococcal Meningitis and Anti-virulence Therapeutic Strategies. Front Microbiol. 2019 Feb 26;10:353. doi:10.3389/fmicb.2019.00353. PMID:30863389.

Thompson GR 3rd, Krois CR, Affolter VK, Everett AD, Varjonen EK, Sharon VR, Singapuri A, Dennis M, McHardy I, Yoo HS, Fedor DM, Wiederhold NP, Aaron PA, Gelli A, Napoli JL, White SD. Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort. Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01384-18. doi:10.1128/AAC.01384-18. PMID:30455235.

Na Pombejra S, Jamklang M, Uhrig JP, Vu K, Gelli A. The structure-function analysis of the Mpr1 metalloprotease determinants of activity during migration of fungal cells across the blood-brain barrier. PLoS One. 2018 Aug 30;13(8):e0203020. doi:10.1371/journal.pone.0203020. PMID:30161190.

Aaron PA, Jamklang M, Uhrig JP, Gelli A. The blood-brain barrier internalises Cryptococcus neoformans via the EphA2-tyrosine kinase receptor. Cell Microbiol. 2018 Mar;20(3):10.1111/cmi.12811. doi:10.1111/cmi.12811. Epub 2018 Jan 18. PMID:29197141.

Gelli A. Exploiting fungal mechanisms to breach the blood-brain barrier. Research Features Magazine. 2016 Dec:103:24-27.

Vu K, Tham R, Uhrig JP, Thompson GR 3rd, Na Pombejra S, Jamklang M, Bautos JM, Gelli A. Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease. mBio. 2014 Jun 3;5(3):e01101-14. doi:10.1128/mBio.01101-14. PMID:24895304.

Vu K, Blumwald E, Gelli A. The Antifungal Activity of HMA, an Amiloride Analog and Inhibitor of Na+/H+ Exchangers. Front Microbiol. 2021 May 5;12:673035. doi:10.3389/fmicb.2021.673035. PMID:34025629.